-85.6%
SMR vs MRNA
+945.0%
-1,030.6%
-86.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.5% | +13.1% | -17.6% | -5.6% |
| 7D | -9.5% | +20.6% | -30.2% | -11.1% |
| 30D | -33.2% | +27.1% | -60.4% | -34.9% |
| 3M | -45.9% | +353.4% | -399.3% | -57.6% |
| 6M | -57.9% | +446.3% | -504.1% | -70.3% |
| YTD | -63.8% | +776.2% | -840.0% | -79.9% |
| 1Y | -85.6% | +987.9% | -1,073.5% | -93.0% |
| All | -85.6% | +945.0% | -1,030.6% | -93.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling